Analgesia induced by the epigenetic drug, L-acetylcarnitine, outlasts the end of treatment in mouse models of chronic inflammatory and neuropathic pain by Notartomaso, Serena et al.
Research Article
Analgesia induced by the epigenetic drug,
L-acetylcarnitine, outlasts the end of
treatment in mouse models of chronic
inflammatory and neuropathic pain
Serena Notartomaso1, Giada Mascio1, Matteo Bernabucci1,
Cristina Zappulla1, Pamela Scarselli1, Milena Cannella1,
Tiziana Imbriglio1, Roberto Gradini1,2, Giuseppe Battaglia1,
Valeria Bruno1,3 and Ferdinando Nicoletti1,3
Abstract
Background: L-acetylcarnitine, a drug marketed for the treatment of chronic pain, causes analgesia by epigenetically
up-regulating type-2 metabotropic glutamate (mGlu2) receptors in the spinal cord. Because the epigenetic mechanisms
are typically long-lasting, we hypothesized that analgesia could outlast the duration of L-acetylcarnitine treatment in
models of inflammatory and neuropathic pain.
Results: A seven-day treatment with L-acetylcarnitine (100mg/kg, once a day, i.p.) produced an antiallodynic effect in the
complete Freund adjuvant mouse model of chronic inflammatory pain. L-Acetylcarnitine-induced analgesia persisted for at
least 14 days after drug withdrawal. In contrast, the analgesic effect of pregabalin, amitryptiline, ceftriaxone, and N-acet-
ylcysteine disappeared seven days after drug withdrawal. L-acetylcarnitine treatment enhanced mGlu2/3 receptor protein
levels in the dorsal region of the spinal cord. This effect also persisted for two weeks after drug withdrawal and was
associated with increased levels of acetylated histone H3 bound to the Grm2 gene promoter in the dorsal root ganglia.
A long-lasting analgesic effect of L-acetylcarnitine was also observed in mice subjected to chronic constriction injury of the
sciatic nerve. In these animals, a 14-day treatment with pregabalin, amitryptiline, tramadol, or L-acetylcarnitine produced
a significant antiallodynic effect, with pregabalin displaying the greatest efficacy. In mice treated with pregabalin, tramadol or
L-acetylcarnitine the analgesic effect was still visible 15 days after the end of drug treatment. However, only in mice treated
with L-acetylcarnitine analgesia persisted 37 days after drug withdrawal. This effect was associated with an increase in
mGlu2/3 receptor protein levels in the dorsal horns of the spinal cord.
Conclusions: Our findings suggest that L-acetylcarnitine has the unique property to cause a long-lasting analgesic effect that
might reduce relapses in patients suffering from chronic pain.
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Introduction
A large body of evidence indicates that L-acetylcarnitine
(LAC) is clinically effective in the treatment of neuro-
pathic pain, fibromyalgia, and other types of chronic
pain, with an excellent profile of safety and tolerabil-
ity.1–10 LAC treatment may also cause antidepressant-
like effects that may be advantageous in the management
of patients suffering from chronic pain.11–14 To our
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knowledge, LAC is the only drug that causes analgesia
via an epigenetic mechanism mediated by acetylation of
p65/RelA, a member of the NFkB family of transcrip-
tion factors. Acetylation of p65/RelA leads to an
enhanced expression of type-2 metabotropic glutamate
(mGlu2) receptors in the dorsal root ganglia and dorsal
horns of the spinal cord with an ensuing reduction of
glutamate release from primary afferent sensory
fibres.15 In rats subjected to chronic constriction injury
(CCI) of the sciatic nerve, repeated administrations of
LAC reduced mechanical allodynia after five to seven
days, and a single injection of an mGlu2/3 receptor
antagonist at the end of LAC treatment was sufficient
to abrogate LAC-induced analgesia.16 Acetylation of
p65/RelA and induction of mGlu2 receptors by LAC
could also be demonstrated in cultured dorsal root gang-
lia neurons, and the induction of mGlu2 receptors was
abrogated by pharmacological inhibition of NFkB.17
Interestingly, drugs that inhibit histone deacetylases
(HDACs) mimicked the analgesic action of LAC and
were also able to enhance p65/RelA acetylation and
mGlu2 receptor expression in the dorsal horns of the
spinal cord.18 That epigenetic regulation of mGlu2
expression is critically involved in the control of pain is
also demonstrated by the evidence that pharmacological
inhibition of histone acetyl transferase (HAT) causes a
marked down-regulation of mGlu2 receptors in the
spinal cord and a hypoacetylation of histones H3 and
H4 in the dorsal root ganglia, thereby preventing the
analgesic activity of the mGlu2/3 receptor agonist,
LY379268.19 LAC treatment was shown to enhance the
amount of acetylated histone H3 acetylation bound to
the promoter of the mGlu2 receptor-encoding gene
(Grm2 gene) in the prefrontal cortex and hippocampus
of spontaneously depressed rats.12 Whether LAC
enhances histone acetylation in the spinal cord of mice
with chronic pain is unknown.
On the basis of these findings, we predicted that LAC
treatment could induce long-lasting changes in the expres-
sion of mGlu2 receptors in the spinal cord resulting into a
persisting analgesic effect. We now demonstrate that
LAC-induced analgesia persists for at least two weeks
after drug withdrawal in the complete Freund adjuvant
(CFA) mouse model of inflammatory pain and for more
than one month in the CCI mouse model of neuropathic
pain. In addition, we offer the first evidence that LAC
treatment enhances the amount of acetylated histone H3
bound to the Grm2 promoter in the dorsal root ganglia.
Materials and methods
Drugs
LAC was a generous gift from Sigma Tau Laboratories
(Pomezia, Italy); N-acetylcysteine (NAC), amitriptyline
and ceftriaxone were purchased from Sigma Aldrich
(St. Louis, MO); pregabalin was purchased from Tocris
Cookson (Avonmouth, Bristol, UK). All these drugs
were dissolved into saline. We used a clinical injectable
formulation of tramadol HCl (Contramal, 50mg/ml),
which was also dissolved into saline.
Animals
We used adult male C57BL/6 J mice (20–25 g, b.w.) pur-
chased from Charles River (Calco, Italy). All mice were
housed five per cage, under a standard 12/12 h light/dark
cycle with food and water ad libitum for at least two
weeks prior to the experiments. All experiments were
carried out according to the European (86/609/EEC)
and Italian (D: Lgs. 116/92) guidelines of animal care.
The experimental protocol was approved by the Italian
Ministry of Health. All efforts were made to minimize
animal suffering and the number of animals.
Induction of chronic inflammatory pain and drug
treatment design
Chronic inflammatory pain was induced by intraplantar
(i.pl.) injections of 20 ml of CFA (F5881 Sigma-Aldrich;
1mg/ml) in the right hind paw. Control mice received an
i.pl. injection of saline. In a first experiment, six groups
of six CFA-injected mice were treated intraperitoneally
(i.p.) as follows: two groups of mice received a single
injection of saline or LAC (100mg/kg) and pain thresh-
olds were assessed after 1 h; the four remaining groups of
mice were treated daily with saline or LAC for either
three or seven days, and pain thresholds were assessed
1 h after the last injection. Mice of the first two groups
were killed 24 h after a single injection of saline or LAC
for the analysis of mGlu2/3 receptor protein levels in the
spinal cord. Mice of all the other groups were killed
immediately after the assessment of pain thresholds. In
a second experiment, four groups of mice were treated as
follows: (1) i.pl. injection of saline followed, 1 h later, by
i.p. injection of saline (once a day for seven days); (2)
i.pl. injection of saline followed by i.p. injection of LAC
(100mg/kg, once a day for seven days); (3) i.pl. injection
of CFA followed by i.p. injection of saline (once a day
for seven days); and (4) i.pl. injection of CFA followed
by i.p. injection of LAC (once a day for seven days).
Mechanical pain thresholds were assessed under basal
conditions (i.e. before i.pl. injection of CFA or saline)
after seven days (i.e. at the end of systemic treatment
with LAC or saline), and seven days after drug with-
drawal (corresponding to 14 days after i.pl. injection of
CFA or saline). Parallel groups of mice injected i.pl. with
CFA and treated with saline or LAC for seven days were
killed at the end of saline or LAC treatment or seven
days later for measurements of mGlu2/3 receptor protein
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levels in the spinal cord. In a third experiment, two
groups of mice were injected i.pl. with CFA and treated
for seven days with either saline or LAC. One week after
drug withdrawal (i.e. 14 days after CFA injection), mice
were killed 1 h after measurements of pain thresholds,
and the dorsal root ganglia were used for chromatin
immunoprecipitation analysis. In a third experiment,
six groups of mice were injected i.pl. with CFA and trea-
ted i.p. once a day for seven days with saline, LAC
(100mg/kg), pregabalin (30mg/kg), amitryptiline
(10mg/kg), ceftriaxone (200mg/kg), or NAC (100mg/kg).
Pain thresholds were assessed prior to CFA injection
(basal), 1 h after the end of drug treatment, and then at
seven and 14 days after drug withdrawal (corresponding
to 14 and 21 days after CFA injection). One hour after
the last injection, three to four mice selected from the
groups treated with i.p. with saline, LAC, or pregabalin
were killed for measurements of mGlu2/3 receptor pro-
tein in the spinal cord.
Induction of neuropathic pain and drug
treatment design
Neuropathic pain was induced by CCI of the sciatic
nerve using the method described by Bennet and Xie20
modified as follows: mice were anesthetized with isoflur-
ane (5% for induction and 2% for maintenance), the
biceps femoris, and gluteus superficialis were separated
by blunt dissection, and the left sciatic nerve was exposed
for ligation. One ligature was tied loosely around the
nerve, until it elicited a brief twitch in the respective
hind limb, taking care to preserve epineural circulation.
The incision was cleaned and the skin was closed with
two to three ligatures of 5-0 dermalon. Mice were then
placed on a warmed surface and, following recovery,
they were returned to their home cages and checked rou-
tinely for 72 h. Five groups of mice (n¼ 7–8 per group)
were treated i.p. daily for 14 days with saline, LAC
(100mg/kg), pregabalin (30mg/kg), amitryptiline
(10mg/kg), or tramadol (100mg/kg). Mechanical
pain thresholds were measured prior to CCI, and at
the end of drug treatment, and then at 7 and 37 days
after drug withdrawal. mGlu2/3 Receptor protein levels
were measured exclusively in CCI mice treated with
saline or LAC.
Measurements of mechanical allodynia
Mechanical allodynia was quantified by measuring the
hind paw withdrawal response to von Frey filament
stimulation. In brief, mice were placed in a Plexiglas
box (20 cm high, 9 cm diameter) with a wire grid
bottom through which the von Frey filaments (North
Coast Medical, Inc., San Jose, CA, USA; bending
force range from 0.008 to 3.5 g) were applied by using
a modified version of the up-down paradigm, as reported
by Chaplan et al.21 The filaments were applied five times
each, in order of increasing forces, and pressed perpen-
dicularly to the plantar surface of the hind paw until they
bent. The first filament that evoked at least three
responses was assigned as the pain threshold in grams.
For the assessment of mechanical sensitivity, mice were
placed in individual cages with elevated mesh floor 1 h
before all behavioral testing.
Western blot analysis
Tissues (dorsal regions of the lumbar segments of the
spinal cord ipsilateral to i.pl. injection of CFA or
saline) were homogenized on ice with RIPA buffer
containing protease inhibitors cocktail tablet (Santa
Cruz Biotechnology, Inc., Temecula, CA, USA).
Homogenates were centrifuged at 14,000 rpmin for
10min and an aliquot was used for protein determin-
ations. Equal amounts of proteins (20 mg) from super-
natants were separated by 8% SDS polyacrilamide gel
and transferred on Immuno PVDF membranes (Bio-
Rad, Milan, Italy) for 7min using Trans Blot Turbo
System (Bio-Rad, Milan, Italy) for the detection of
mGlu2/3 receptor. Filters were blocked overnight in
blocking buffer (TBS, 0.05% Tween-20 and 5%
non-fat milk) at 4C. Membrane were incubated for
1 h with rabbit polyclonal anti-mGlu2/3 receptors
(1:500, Sigma-Aldrich), and secondary peroxidase-
coupled anti-rabbit antibodies (1:7000 Calbiochem,
Milano, Italy). The blots were re-probed with anti-b-
actin monoclonal antibody (1:50,000 Sigma-Aldrich).
Immunostaining was revealed by enhanced chemilumin-
escence luminosity (Amersham Pharmacia Biotech,
Arlington Height, IL).
Chromatin immunoprecipitation assay
Chromatin immunoprecipitation assay was performed
by standard procedures. Briefly, dorsal root ganglia
were cross-linked using 1% formaldehyde at room
temperature for 10min. The cross-linking reaction was
stopped by adding glycine to a final concentration of
0.125M. Tissue was then washed three times with
ice-cold PBS supplemented with protease inhibitors
(Sigma-Aldrich), homogenized in lysis buffer (5mM
PIPES pH 8.0, 85mM KCl, 0.5% NP40, protease inhibi-
tors), and nuclei lysis buffer (1% SDS, 10mM EDTA,
50mM Tris-HCl pH 8.0, protease inhibitors), and then
sonicated on ice using a Covaris S220 ultrasonicator.
Following sonication, chromatin fragments of 0.2–0.6 kb
in length were obtained. Ten percent of the sonicated
lysate was saved and successively used to quantify
the total amount of DNA present in different samples
before immunoprecipitation (inputs). The chromatin
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solution was precleared with salmon sperm DNA/
protein A-agarose 50% gel slurry for 1 h at 4C and
immunoprecipitated overnight at 4C with antibodies
against pan-acetylated-H3 histone (6mg/ml, Upstate
Biotechnology, Billerica, MA, USA) or the respective
isotype matched control Ig. After precipitation, the chro-
matin-antibody complexes were collected using Protein
A Sepharose beads and washed. Samples were then
eluted with 1% SDS, 100mM NaHCO3 at room
temperature for 15min, reverse cross-linked with NaCl
100mM at 65C overnight, and treated with proteinase-K.
Levels of histone acetylation at the Grm2 gene
promoter were expressed as percentage of the input
DNA that was immunoprecipitated by the anti-acetyl-
histone H3 antibody using the following equation:
% (acetDNA-IP/total input)¼ 2 [(Ct(10%input) 3.32)
Ct (acetDNAIP)]100%.
Statistical analysis
Statistical analysis was performed by one-way ANOVA
or two-way ANOVA for repeated measures followed by
Fisher’s LSD or, alternatively, by Student’s t-test, as
indicated.
Results
LAC produced long-lasting analgesia and a long-lasting
increase in mGlu2/3 receptor protein levels in the CFA
model of chronic inflammatory pain
LAC treatment is known to produce analgesia in the
CCI model of neuropathic pain after at least five days
of daily injections.16 First, we examined whether LAC
was also able to produce analgesia in the CFA model
with a similar temporal profile. i.pl. CFA injection
induced a large reduction in pain thresholds, which per-
sisted for at least two weeks. LAC failed to induce
changes in mechanical pain thresholds after a single
administration or three days of injections, but produced
substantial analgesia after seven days of daily injections
(Figure 1(a)). To examine whether the effect of LAC
outlasted the end of treatment, we performed a second
experiment in which LAC or saline were administered
daily for seven days. Pain thresholds were assessed at
the end of the treatment and, again, seven days later.
LAC treatment produced substantial analgesia in CFA-
injected mice at both time points (Figure 1(b)). LAC
treatment did not significantly affect mechanical thresh-
olds in control mice that received i.pl. injection of saline
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Figure 1. Effect of LAC on mechanical pain thresholds in the CFA mouse model of chronic inflammatory pain. (a) Six groups of six CFA-
injected mice were treated intraperitoneally (i.p.) as follows: two groups of mice received a single injection of saline or LAC (100mg/kg)
and pain thresholds were assessed after 1 h; the four remaining groups of mice were treated daily with saline or LAC for either three or
seven days, and pain thresholds were assessed 1 h after the last injection. Values are means S.E.M. of six determinations per group.
*p< 0.05 (two-way ANOVAþ Fisher’s LSD; F(5,25)¼ 11.13). Mechanical pain thresholds in mice injected i.pl. with saline or CFA and then
treated i.p. with either LAC (100mg/kg, once a day for seven days) or saline are shown in (b). Thresholds were measured under basal
conditions (i.e. prior to i.pl. injections of saline or CFA), at the end of the seven days of treatment with saline or LAC (1 h of withdrawal),
and again after seven days of withdrawal. Values are means S.E.M. of five to seven determinations. p< 0.01 vs. the corresponding values
obtained in mice injected i.pl. and i.p. with saline (*) or vs. the corresponding values obtained in mice injected i.pl. with CFA and i.p. with
saline (#) (two-way ANOVA for repeated measuresþ Fisher’s LSD; treatment x time F(8,24)¼ 4.975).
CFA: complete Freund adjuvant; LAC: L-acetylcarnitine.
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instead of CFA (Figure 1(b)). Moving from the evidence
that induction of mGlu2 receptors mediates the analgesic
action of LAC,16 we measured mGlu2/3 receptor protein
levels in the dorsal regions of the lumbar spinal cord
ipsilateral to the site of CFA injection. Western blot ana-
lysis showed two bands at 100–110 KDa, of which the
upper band corresponds to mGlu2/3 receptor mono-
mers, and an additional band at >200 kDa correspond-
ing to the active, dimeric form of mGlu2/3 receptor.
LAC had no effect on mGlu2/3 receptor protein levels
after a single administration or three days of treatment
(Figure 2(a)). In contrast, seven days of treatment with
LAC enhanced mGlu2/3 receptor protein levels in the
dorsal region of the lumbar spinal cord. This effect per-
sisted after seven days of drug withdrawal (data of the
two experiments are similar, and only data of the second
experiment are shown in Figure 2(b)).
Increased levels of acetylated histone H3 bound to the
Grm2 gene promoter in the dorsal root ganglia one
week after LAC treatment in CFA mice
Induction of mGlu2 receptors by LAC in the dorsal root
ganglia and spinal cord has been related to an increased
acetylation of p65/RelA.17 However, acetylation of a
transcription factor may not be sufficient to explain the
long-lasting increase in mGlu2/3 receptor protein we
have seen in mice treated with LAC. Thus, we examined
whether LAC treatment was also able to enhance histone
acetylation on the Grm2 gene promoter in the dorsal root
ganglia as already observed in other brain regions.12 Two
additional groups of mice injected with CFA were trea-
ted with saline or LAC for seven days, and killed seven
days later. We could confirm in these mice that LAC
induced an analgesic effect that outlasted the end of
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Figure 2. Repeated injections of LAC induced an increase in mGlu2/3 receptor protein levels that outlasted the end of drug treatment.
mGlu2/3 protein levels were measured in the dorsal regions of the lumbar spinal cord ipsilateral to CFA injection. Data in (a) and (b) were
obtained by the same groups of mice as in Figure 1(a) and (b), respectively. Mice treated with a single injection of saline or LAC were killed
after 24 h. Mice treated with saline or LAC for three or seven days were killed pain assessment 1 h following the last injection. Data at
seven days from animals used in Figure 1(a) are not shown. Values are meansþ S.E.M. of four to five and 5–10 determinations in (a) and (b),
respectively. *p< 0.05 vs. the corresponding values of mice treated i.p. with saline (one-way ANOVAþ Fisher’s LSD; F(3,23)¼ 5.884).
Wdt: withdrawal; CFA: complete Freund adjuvant; mGlu2: type-2 metabotropic glutamate.
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treatment (Figure 3(a)). ChIP analysis showed an
increased acetylation of histone H3 bound to the Grm2
promoter in the dorsal root ganglia of LAC-treated mice
after seven days of withdrawal, as compared to mice
treated with saline (Figure 3(b)).
LAC was the only tested analgesic drug that produced
a long-lasting increase in pain thresholds in the CFA
model of chronic inflammatory pain
Mice injected i.pl. with CFA were treated for seven days
with either saline, LAC (100mg/kg), pregabalin (30mg/kg),
amitriptyline (10mg/kg), ceftriaxone (200mg/kg), or
N-acetylcysteine (NAC, 100mg/kg). All drugs produced
similar analgesic effects at the end of treatment, but only
mice treated with LAC retained the analgesic at seven or
14 days after drug withdrawal (Figure 4(a)). Selected
mice treated with saline, LAC, or pregabalin were also
used for measurements of mGlu2/3 receptor protein
levels in the dorsal region of the spinal cord after the
last determination of pain thresholds. LAC-treated
mice showed increased mGlu2/3 receptor protein levels
after 14 days of drug withdrawal (Figure 4(b)), whereas a
small reduction in mGlu2/3 receptor protein levels was
observed in the group of mice treated with pregabalin
(Figure 4(c)).
Long-lasting analgesic effect of LAC in the CCI mouse
model of neuropathic pain
Mice subjected to CCI of the sciatic nerve were treated
daily for 14 days, i.p., with either saline, LAC (100mg/
kg), pregabalin (30mg/kg), amitriptyline (10mg/kg), or
tramadol (100mg/kg), and mechanical pain thresholds
were measured 1 h after the end of treatments and at 7
and 37 days after drug withdrawal. CCI mice treated
with saline showed the expected reduction in mechanical
pain threshold as compared to sham-operated mice. At
least under our conditions, mechanical allodynia
remained stable up to 51 days after CCI in saline-treated
mice (Figure 5(a)). At the end of systemic treatments
(i.e. 14 days after CCI), a significant increase in pain
thresholds was seen in all groups of mice treated with
drugs, with pregabalin displaying the greatest analgesic
effect (Figure 5(a)). Seven days after the end of treat-
ments, analgesia was still observed in mice treated with
pregabalin, tramadol, or LAC, but not in mice treated
with amitryptiline (Figure 5(a)). In contrast, only mice
treated with LAC still showed a significant increase in
pain thresholds 37 days after drug withdrawal
(Figure 5(a)). An increase in mGlu2/3 receptor protein
levels was observed in the ipsilateral dorsal horns of the
spinal cord of the group of mice treated with LAC after
37 days of withdrawal as compared to mice treated with
saline (Figure 5(b)).
Discussion
A number of recent reviews highlight the role of epigen-
etic mechanisms in the pathophysiology and treatment of
chronic pain.22–26 Changes in histone acetylation have
been consistently found in the pain neuraxis of mice
developing chronic inflammatory or neuropathic pain.
CFA-induced inflammatory pain is associated with an
increased expression of class-II HDACs in the dorsal
horns of the spinal cord.27 Spinal nerve ligation causes
a reduced acetylation of histone H3 bound to the pro-
moter of the gene encoding for the GABA-synthesizing
enzyme, glutamate decarboxylase-65, in the nucleus
raphe magnus, resulting into a disinhibition of serotoner-
gic neurons projecting to the spinal cord.28 In models of
neuropathic pain, changes in acetylation mechanisms
affect the expression of genes encoding for proteins
that critically regulate pain thresholds, such as m opiate
receptors, Kv4.3 potassium channels, Nav1.8 voltage-
sensitive sodium channels, and brain-derived neuro-
trophic factor.28–31 Drugs that enhance acetylation of
histones or transcription factors, such as HDAC inhibi-
tors, consistently cause analgesia in models of
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Figure 3. Increased levels of acetylated histone H3 bound to the
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inflammatory pain treated with LAC. Mice were injected i.pl. with
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CFA: complete Freund adjuvant.
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F(23,161)¼ 6.399. mGlu2/3 receptor protein levels in the dorsal region of the ipsilateral lumbar spinal cord of the same groups of mice
treated with saline, LAC or pregabalin are shown in (b), where values are means S.E.M. of three to four determinations. *p< 0.05 vs.
values obtained in mice treated with saline (Student’s t-test; t¼ 3.199 for pregabalin and t¼24.07 for LAC).
CFA: complete Freund adjuvant; LAC: L-acetylcarnitine; mGlu2: type-2 metabotropic glutamate.
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inflammatory and neuropathic pain, although histone
acetyl-transferase inhibitors may also relieve pain.24
The acetylating agent, LAC, causes analgesia by enhan-
cing the expression of mGlu2 receptors in the dorsal root
ganglia and dorsal horns of the spinal cord.15–17 At least
a component of the analgesic action of LAC is mediated
by acetylation of NFkB p65/RelA, which enhances its
transcriptional activity at the Grm2 gene promoter.17
This mechanism is shared by at least two HDAC inhibi-
tors, which were shown to cause analgesia in the second
phase of the formalin test by up-regulating mGlu2
receptors.18
LAC is a safe drug that is currently marketed for the
treatment of chronic pain (see Introduction section and
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Figure 5. Comparative effects of LAC and other analgesic drugs on pain thresholds in the CCI model of neuropathic pain. Mice were
subjected to CCI of the sciatic nerve and then treated i.p. once a day for 14 days with either saline, LAC (100mg/kg), pregabalin (30mg/kg),
tramadol (100mg/kg), or amitryptiline (10mg/kg). Pain thresholds were measured under basal conditions, at the end of drug treatments,
and then after 7 or 37 days. Data are shown in (a). Basal pain thresholds are not shown and were similar in all experimental groups. Values
are means S.E.M. of seven to eight determinations. *p< 0.05 (one-way ANOVA for repeated measuresþ Fisher’s LSD; F(14,89)¼ 8.984).
mGlu2/3 protein levels in the ipsilateral dorsal region of the lumbar spinal cord of mice treated with saline or LAC at the end of experiment
(i.e. after 37 days of withdrawal) are shown in (b). Values are means S.E.M. of seven determinations. Two samples from sham-operated
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with saline.
CCI: chronic constriction injury; LAC: L-acetylcarnitine; mGlu2: type-2 metabotropic glutamate.
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references section therein). However, LAC is not con-
sidered as a first-line drug in the treatment of inflamma-
tory, mixed, or neuropathic pain32 in spite of its
widespread use in the medical practice. Our data
demonstrate that LAC has the unique property to pro-
duce an analgesic effect that outlasts by several days or
weeks the end of treatment in models of chronic inflam-
matory and neuropathic pain. This strengthens the value
of LAC as an analgesic drug and supports the hypothesis
that epigenetic mechanisms are valuable candidate drug
targets in the treatment of chronic pain. As active com-
parators, we used drugs that are known to cause anal-
gesia by targeting mechanisms that regulate pain
threshold in the spinal cord and other region of the
pain neuraxis. Pregabalin binds to the a2d subunit of
voltage-sensitive Ca2þ channels, thereby restraining
neurotransmitter release at the synapses between pri-
mary afferent fibres and spinal cord neurons.33
Pregabalin also prevents the increased transport of the
a2d subunit from dorsal root ganglia to the spinal cord
associated with neuropathic pain,34 thus weakening the
molecular machinery that allows Ca2þ entry in the pre-
synaptic terminals of primary sensory fibres. Although
pregabalin is a first-line drug in the treatment of neuro-
pathic pain,32 it also shows efficacy in the CFA model of
chronic inflammatory pain.35 Amiptryptiline is a tricyclic
antidepressant that is also used as a first-line drug in the
treatment of neuropathic pain32 and acts primarily by
inhibiting noradrenaline and serotonin uptake from pre-
synaptic terminals. However, amitryptiline exerts pleio-
tropic effects that widen its action to different types of
pain, such as inhibition of TrpV1 channels36 and induc-
tion of endogenous opioid release.37 Tramadol is a m
opioid receptor agonist that can also inhibit serotonin
and noradrenaline uptake and is widely used in the treat-
ment of different types of pain including neuropathic
pain.32 Ceftriaxone is a b-lactam antibiotic that induces
the expression of the glial glutamate transporter, GLT-1,
thereby causing analgesia in experimental animal models
and humans.38–40 NAC is an activator of the cystine-
glutamate antiporter that causes analgesia by enhancing
the endogenous activation of mGlu2 receptors.41,42 We
used all these drugs at a single dose, selected in conform-
ity with previous reports.16,35,40–44 In the CFA model of
chronic inflammatory pain, all drugs were equally effect-
ive in increasing mechanical pain thresholds, but only in
mice treated with LAC the analgesic effect was still
observed after one or two weeks of drug withdrawal.
In the CCI model, pregabalin and amitryptiline dis-
played the greatest efficacy in causing analgesia, as
expected by their first-line indication in the treatment
of neuropathic pain.32 Interestingly, the analgesic effect
of pregabalin and tramadol persisted after one week of
drug withdrawal, whereas the effect of amitryptiline was
not durable. Pregabalin-induced analgesia outlasted the
end of treatment in mice with neuropathic pain but not
in mice with chronic inflammatory pain. In mice with
neuropathic pain, pregabalin may cause a prolonged
analgesia by preventing the increased trafficking of the
a2d subunit from the dorsal root ganglia to the spinal
cord.34 LAC was less efficacious than pregabalin in
enhancing mechanical pain thresholds in CCI mice, but
its effect persisted after five weeks of drug withdrawal,
when the effect of all other drugs was no longer visible.
The long-lasting effects of LAC in the CFA and CCI
models of chronic pain suggest that the drug causes per-
sistent changes in the molecular machinery that controls
pain threshold in the CNS. LAC is known to induce the
expression of mGlu2 receptors by enhancing the acetyl-
ation of the transcription factor, p65/RelA.15–17 This
mechanism has been clearly demonstrated in in vitro
and in vivo models,11,12,17 but it is insufficient to explain
the induction of mGlu2 receptors we have seen in the
spinal cord of CFA and CCI mice after weeks of drug
withdrawal. At least in CFA mice, we have demonstrated
that levels of acetylated histone H3 bound to Grm2 pro-
moter were elevated in LAC-treated animals after two
weeks of withdrawal. This suggests that LAC-induced
acetylation is not restricted to transcription factors,
and that durable changes in chromatin structure caused
by histone acetylation may underlie an analgesic effect
that outlasts by several days or weeks the end of LAC
treatment. It is likely that LAC enhanced histone acetyl-
ation acting as an acetyl donor at the Grm2 promoter.
However, we cannot exclude that LAC acts indirectly to
enhance H3 histone acetylation at the Grm2 promoter.
For example, LAC might acetylate a transcription factor
that represses HDAC expression, thereby enhancing his-
tone acetylation.
An increased histone acetylation by LAC has already
been found in the hippocampus and prefrontal cortex of
spontaneously depressed Flinders Sensitive Line rats,
where LAC was shown to induce a long-lasting antide-
pressant-like effect.12 It is therefore possible that acetyl-
ation of both p65/Rel and histones contributes to Grm2
induction in response to LAC, and that histone acetyl-
ation in particular accounts for the long-lasting increase
in mGlu2 receptor expression and analgesia in models of
chronic pain. A direct correlation between histone acetyl-
ation and mGlu2/3 receptor expression in the spinal cord
has been demonstrated in a model of stress-induced irrit-
able bowel disorder, in which HDAC inhibition attenu-
ates visceral hypersensitivity by enhancing the levels of
acetylated histone H3 bound to Grm2 and Grm3
promoters.45
mGlu2 and mGu3 receptors are expressed in all sta-
tions of the pain neuraxis, and their activation consist-
ently produces analgesia in a variety of pain models.46–56
At least in the formalin model of inflammatory pain,
mGlu2 rather than mGlu3 receptors appear to regulate
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pain threshold and mediate the analgesic activity of
mGlu2/3 receptor agonists.57 Thus, our findings support
the hypothesis15 that targeting the epigenetic mechan-
isms that regulate mGlu2 receptor expression may be a
valuable strategy for an efficient and durable treatment
of chronic pain.
Conclusions
We have shown that LAC, a drug marketed for the treat-
ment of chronic pain, produces a long-lasting analgesia in
mouse models of inflammatory and neuropathic pain.
Analgesia outlasted by several days or weeks the end of
treatment. This property was unique to LAC in mice with
chronic inflammatory pain, and was also shared by preg-
abalin and tramadol in mice with neuropathic pain.
However, at a late time point after drug withdrawal,
only mice with neuropathic pain treated with LAC
retained the analgesic effect. An increase in histone acetyl-
ation at Grm2 gene promoter may contribute to the long-
lasting analgesic effect of LAC. These findings suggest
that LAC may relieve pain for a long time causing a per-
sistent up-regulation of mGlu2 receptors, which are key
players in the regulation of pain threshold. These findings
strengthen the value of mGlu receptors as drug targets for
the treatment of pain.58–62 The peculiar mechanism of
action of LAC is promising from a clinical standpoint
considering that the benefit achieved with current anal-
gesic drugs in patients suffering of neuropathic pain and
other types of chronic pain is suboptimal and a large per-
centage of patients is resistant to medication.63 Our data
encourage clinical studies with LAC in patients suffering
from chronic inflammatory or neuropathic pain in which
the relapse rate at different time intervals after drug with-
drawal is included as a primary endpoint.
Author Contributions
SN and GM contributed equally to this article. SN, GM,
MB, CZ, PS, MC, TI: performed experiments and ana-
lyzed data; RG, GB, VB, FN: designed experiments,
supervised research and wrote the manuscript. All
authors read and approved the final manuscript.
Declaration of Conflicting Interests
The author(s) declared no potential conflicts of interest
with respect to the research, authorship, and/or publica-
tion of this article.
Funding
The author(s) disclosed receipt of the following financial sup-
port for the research, authorship, and/or publication of this
article: This work was supported by the Italian Ministry of
Health (project code: RF-2011-02352582).
References
1. Onofrj M, Fulgente T, Melchionda D, et al. L-acetylcarni-
tine as a new therapeutic approach for peripheral neuro-
pathies with pain. Int J Clin Pharmacol Res 1995; 15: 9–15.
2. Sima AA, Calvani M, Mehra M, et al. Acetyl-L-carnitine
improves pain, nerve regeneration, and vibratory percep-
tion in patients with chronic diabetic neuropathy: an ana-
lysis of two randomized placebo-controlled trials. Diabetes
Care 2005; 28: 89–94.
3. Flatters SJ, Xiao WH and Bennett GJ. Acetyl-L-carnitine
prevents and reduces paclitaxel-induced painful peripheral
neuropathy. Neurosci Lett 2006; 397: 219–223.
4. Evans JD, Jacobs TF and Evans EW. Role of acetyl-L-
carnitine in the treatment of diabetic peripheral neur-
opathy. Ann Pharmacother 2008; 42: 1686–1691.
5. Memeo A and Loiero M. Thioctic acid and acetyl-L-carni-
tine in the treatment of sciatic pain caused by a herniated
disc: a randomized, double-blind, comparative study. Clin
Drug Investig 2008; 28: 495–500.
6. Xiao WH and Bennett GJ. Chemotherapy-evoked neuro-
pathic pain: abnormal spontaneous discharge in A-fiber
and C-fiber primary afferent neurons and its suppression
by acetyl-L-carnitine. Pain 2008; 135: 262–270.
7. Janiri L, Martinotti G, Tonioni F, et al. Acetyl-L-carnitine
in the management of pain during methadone withdrawal
syndrome. Clin Neuropharmacol 2009; 32: 35–40.
8. Valcour V, Yeh TM, Bartt R, Clifford D, et al. Acetyl-l-
carnitine and nucleoside reverse transcriptase inhibitor-
associated neuropathy in HIV infection. HIV Med 2009;
10: 103–110.
9. Leombruni P, Miniotti M, Colonna F, et al. A randomised
controlled trial comparing duloxetine and acetyl L-carni-
tine in fibromyalgic patients: preliminary data. Clin Exp
Rheumatol 2015; 33: S82–S85.
10. Li S, Li Q, Li Y, et al. Acetyl-L-carnitine in the treatment
of peripheral neuropathic pain: a systematic review and
meta-analysis of randomized controlled trials. PLoS One
2015; 10: e0119479.
11. Cuccurazzu B, Bortolotto V, Valente MM, et al.
Upregulation of mGlu2 receptors via NF-kB p65 acetyl-
ation is involved in the Proneurogenic and antidepressant
effects of acetyl-L-carnitine. Neuropsychopharmacology
2013; 38: 2220–2230.
12. Nasca C, Xenos D, Barone Y, et al. L-acetylcarnitine
causes rapid antidepressant effects through the epigenetic
induction of mGlu2 receptors. Proc Natl Acad Sci USA
2013; 110: 4804–4809.
13. Zanardi R and Smeraldi E. A double-blind, randomised,
controlled clinical trial of acetyl-L-carnitine vs. amisulpride
in the treatment of dysthymia. Eur Neuropsychopharmacol
2006; 16: 281–287.
14. Bersani G, Meco G, Denaro A, et al. L-Acetylcarnitine in
dysthymic disorder in elderly patients: a double-blind, mul-
ticenter, controlled randomized study vs. fluoxetine. Eur
Neuropsychopharmacol 2013; 23: 1219–1225.
15. Chiechio S, Copani A, Zammataro M, et al.
Transcriptional regulation of type-2 metabotropic glutam-
ate receptors: an epigenetic path to novel treatments for
chronic pain. Trends Pharmacol Sci 2010; 31: 153–160.
10 Molecular Pain
16. Chiechio S, Caricasole A, Barletta E, et al.
L-Acetylcarnitine induces analgesia by selectively up-
regulating mGlu2 metabotropic glutamate receptors.
Mol Pharmacol 2002; 61: 989–996.
17. Chiechio S, Copani A, De Petris L, et al. Transcriptional
regulation of metabotropic glutamate receptor 2/3 expres-
sion by the NF-kappaB pathway in primary dorsal root
ganglia neurons: a possible mechanism for the analgesic
effect of L-acetylcarnitine. Mol Pain 2006; 2: 20.
18. Chiechio S, Zammataro M, Morales ME, et al. Epigenetic
modulation of mGlu2 receptors by histone deacetylase
inhibitors in the treatment of inflammatory pain. Mol
Pharmacol 2009; 75: 1014–1020.
19. Zammataro M, Sortino MA, Parenti C, et al. HDAC and
HAT inhibitors differently affect analgesia mediated by
group II metabotropic glutamate receptors. Mol Pain
2014; 10: 68.
20. Bennett GJ and Xie YK. A peripheral mononeuropathy in
rat that produces disorders of pain sensation like those
seen in man. Pain 1988; 33: 87–107.
21. Chaplan SR, Bach FW, Pogrel JW, et al. Quantitative
assessment of tactile allodynia in the rat paw. J Neurosci
Methods 1994; 53: 55–63.
22. Kurita M, Moreno JL, Holloway T, et al. Repressive epi-
genetic changes at the mGlu2 promoter in frontal cortex of
5-HT2A knockout mice. Mol Pharmacol 2013; 83:
1166–1175.
23. Descalzi G, Ikegami D, Ushijima T, et al. Epigenetic
mechanisms of chronic pain. Trends Neurosci 2015; 38:
237–246.
24. Ge´ranton SM and Tochiki KK. Could targeting epigenetic
processes relieve chronic pain states? Curr Opin Support
Palliat Care 2015; 9: 138–146.
25. Ge´ranton SM and Tochiki KK. Regulation of gene expres-
sion and pain states by epigenetic mechanisms. Prog Mol
Biol Transl Sci 2015; 131: 147–183.
26. Liang L, Lutz BM, Bekker A, et al. Epigenetic regulation
of chronic pain. Epigenomics 2015; 7: 235–245.
27. Bai G, Wei D, Zou S, et al. Inhibition of class II histone
deacetylases in the spinal cord attenuates inflammatory
hyperalgesia. Mol Pain 2010; 6: 51.
28. Zhang Z, Cai YQ, Zou F, et al. Epigenetic suppression of
GAD65 expression mediates persistent pain. Nat Med
2011; 17: 1448–1455.
29. Uchida H, Ma L and Ueda H. Epigenetic gene silencing
underlies C-fiber dysfunctions in neuropathic pain.
J Neurosci 2010; 30: 4806–4814.
30. Uchida H, Matsushita Y and Ueda H. Epigenetic regula-
tion of BDNF expression in the primary sensory neurons
after peripheral nerve injury: implications in the develop-
ment of neuropathic pain. Neuroscience 2013; 240:
147–154.
31. Uchida H, Sasaki K, Ma L, et al. Neuron-restrictive silen-
cer factor causes epigenetic silencing of Kv4.3 gene after
peripheral nerve injury. Neuroscience 2010; 166: 1–4.
32. Attal N, Cruccu G, Baron R, et al. EFNS guidelines on the
pharmacological treatment of neuropathic pain: 2010 revi-
sion. European Federation of Neurological Societies. Eur J
Neurol 2010; 17: 1113–e88.
33. Dooley DJ, Taylor CP, Donevan S, et al. Ca2þ channel
alpha2delta ligands: novel modulators of neurotransmis-
sion. Trends Pharmacol Sci 2007; 28: 75–82.
34. Bauer CS, Nieto-Rostro M, Rahman W, et al. The
increased trafficking of the calcium channel subunit
alpha2delta-1 to presynaptic terminals in neuropathic
pain is inhibited by the alpha2 delta ligand pregabalin.
J Neurosci 2009; 29: 4076–4088.
35. Maciel IS, Silva RB, Morrone FB, et al. Synergistic effects
of celecoxib and bupropion in a model of chronic inflam-
mation-related depression in mice. PLoS One 2013; 8:
e77227.
36. Ola´h Z, Jo´svay K, Pecze L, et al. Anti-calmodulins and
tricyclic adjuvants in pain therapy block the TRPV1 chan-
nel. PLoS One 2007; 2: e545.
37. Gray AM, Spencer PS and Sewell RD. The involvement of
the opioidergic system in the antinociceptive mechanism of
action of antidepressant compounds. Br J Pharmacol 1998;
124: 669–674.
38. Lin Y, Tian G, Roman K, et al. Increased glial glutamate
transporter EAAT2 expression reduces visceral nociceptive
response in mice. Am J Physiol Gastrointest Liver Physiol
2009; 296: G129–G134.
39. Chen Z, He Y and Wang ZJ. The beta-lactam antibiotic,
ceftriaxone, inhibits the development of opioid-induced
hyperalgesia in mice. Neurosci Lett 2012; 509: 69–71.
40. Macaluso A, Bernabucci M, Trabucco A, et al. Analgesic
effect of a single preoperative dose of the antibiotic cef-
triaxone in humans. J Pain 2013; 14: 604–612.
41. Bernabucci M1, Notartomaso S, Zappulla C, et al.
N-Acetyl-cysteine causes analgesia by reinforcing the
endogenous activation of type-2 metabotropic glutamate
receptors. Mol Pain 2012; 8: 77.
42. Truini A, Piroso S, Pasquale E, et al. N-acetyl-cysteine, a
drug that enhances the endogenous activation of group-II
metabotropic glutamate receptors, inhibits nociceptive
transmission in humans. Mol Pain 2015; 11: 14.
43. Jesse CR, Wilhelm EA and Nogueira CW. Depression-like
behavior and mechanical allodynia are reduced by bis sel-
enide treatment in mice with chronic constriction injury: a
comparison with fluoxetine, amitriptyline, and bupropion.
Psychopharmacology 2010; 212: 513–522.
44. Mika J, Jurga AM, Starnowska J, et al. Effects of chronic
doxepin and amitriptyline administration in naı¨ve mice and
in neuropathic pain mice model. Neuroscience 2015; 294:
38–50.
45. Cao DY, Bai G, Ji Y, et al. Histone hyperacetylation
modulates spinal type II metabotropic glutamate receptor
alleviating stress-induced visceral hypersensitivity in female
rats. Mol Pain 2016; 12: 1–12.
46. Neugebauer V, Chen PS and Willis WD. Groups II and III
metabotropic glutamate receptors differentially modulate
brief and prolonged nociception in primate STT cells.
J Neurophysiol 2000; 84: 2998–3009.
47. Popik P, Kozela E and Pilc A. Selective agonist of group II
glutamate metabotropic receptors, LY354740, inhibits
tolerance to analgesic effects of morphine in mice. Br J
Pharmacol 2000; 130: 1425–1431.
48. Simmons RM, Webster AA, Kalra AB, et al. Group II
mGluR receptor agonists are effective in persistent and
Notartomaso et al. 11
neuropathic pain models in rats. Pharmacol Biochem Behav
2002; 73: 419–427.
49. Yang D and Gereau RW 4th. Peripheral group II metabo-
tropic glutamate receptors mediate endogenous anti-allo-
dynia in inflammation. Pain 2003; 106: 411–417.
50. Yang D and Gereau RW 4th. Peripheral group II
metabotropic glutamate receptors (mGluR2/3) regulate
prostaglandin E2-mediated sensitization of capsaicin
responses and thermal nociception. J Neurosci 2002; 22:
6388–6393.
51. Jones CK, Eberle EL, Peters SC, et al. Analgesic effects of
the selective group II (mGlu2/3) metabotropic glutamate
receptor agonists LY379268 and LY389795 in persistent
and inflammatory pain models after acute and repeated
dosing. Neuropharmacology 2005; 49: 206–218.
52. Du J, Zhou S and Carlton SM. Group II metabotropic
glutamate receptor activation attenuates peripheral sensi-
tization in inflammatory states. Neuroscience 2008; 154:
754–766.
53. Carlton SM, Du J and Zhou S. Group II metabotropic
glutamate receptor activation on peripheral nociceptors
modulates TRPV1 function. Brain Res 2009; 1248: 86–95.
54. Zhou HY, Chen SR, Chen H, et al. Functional plasticity
of group II metabotropic glutamate receptors in
regulating spinal excitatory and inhibitory synaptic input
in neuropathic pain. J Pharmacol Exp Ther 2011; 336:
254–264.
55. Asseri KA, Puil E, Schwarz SK, et al. Group II metabo-
tropic glutamate receptor antagonism prevents the
antiallodynic effects of R-isovaline. Neuroscience 2015;
293: 15–156.
56. Kiritoshi T and Neugebauer V. Group II mGluRs modu-
late baseline and arthritis pain-related synaptic transmis-
sion in the rat medial prefrontal cortex.
Neuropharmacology 2015; 95: 388–394.
57. Zammataro M, Chiechio S, Montana MC, et al. mGlu2
metabotropic glutamate receptors restrain inflammatory
pain and mediate the analgesic activity of dual mGlu2/
mGlu3 receptor agonists. Mol Pain 2011; 7: 6.
58. Neugebauer V. Peripheral metabotropic glutamate recep-
tors: fight the pain where it hurts. Trends Neurosci 2001;
24: 550–552.
59. Neugebauer V. Metabotropic glutamate receptors –
important modulators of nociception and pain behavior.
Pain 2002; 98: 1–8.
60. Goudet C, Magnaghi V, Landry M, et al. Metabotropic
receptors for glutamate and GABA in pain. Brain Res Rev
2009; 60: 43–56.
61. Montana MC and Gereau RW. Metabotropic glutamate
receptors as targets for analgesia: antagonism, activation,
and allosteric modulation. Curr Pharm Biotechnol 2011; 12:
1681–1688.
62. Brumfield S, Korakas P, Silverman LS, et al. Synthesis and
SAR development of novel mGluR1 antagonists for the
treatment of chronic pain. Bioorg Med Chem Lett 2012;
22: 7223–7226.
63. Eisenstein M. Neuropathy: a name for their pain. Nature
2016; 535: S10–S11.
12 Molecular Pain
